Phase I study of UFT plus leucovorin with radiotherapy in patients with inextirpable non-rectal gastrointestinal cancer

Radiotherapy and Oncology

Volumn 70, Issue 2, 2004, Pages 171-175

  Bystrom P ^a   Frodin J E ^a   Berglund, A ^b   Wilking, N ^a,c   Glimelius, B ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Gastrointestinal cancer; Oral fluoropyrimidines; Phase I trial; Radio chemotherapy

Indexed keywords

FOLINIC ACID; UFT;

ADULT; AGED; BLADDER DISEASE; BLOOD TOXICITY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; HUMAN; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RADIATION DOSE; THROMBOCYTOPENIA; TOXICITY; TREATMENT INDICATION; TREATMENT PLANNING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL NEOPLASMS; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL ANALYSIS; TEGAFUR; TERMINALLY ILL; TREATMENT OUTCOME; URACIL;

EID: 1542603282     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2004.01.004     Document Type: Conference Paper

References (20)

1. Chavaudra J., Bridier A. Definition of volumes in external radiotherapy: ICRU reports 50 and 62. Cancer Radiother. 5:2001;472-478.
2. Feliu J., Calvilio J., Escribano A., et al. Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy. Ann Oncol. 13:2002;730-736.
3. Glimelius B. Chemoradiotherapy for rectal cancer - is there an optimal combination? Ann Oncol. 12:2001;1039-1045.
4. Glimelius B., Gronberg H., Jarhult J., Wallgren A., Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol. 42:2003;476-492.
5. Gunderson L.L., Burch P.A., Donohue J.H. The role of irradiation as a component of combined modality treatment for gastric cancer. J Infus Chemother. 5:1995;117-124.
6. Gunderson L.L. Indications for and results of combined modality treatment of colorectal cancer. Acta Oncol. 38:1999;7-21.
7. Gundersson L.L. Principles and practice of radiation oncology. 3rd ed:1997;Lippincott, Philadelphia, PA. p. 1467-88.
8. Hirata K., Sasaki K., Yamamitsu S., Shirasaka T. A comparison of 5-fluorouracil concentration of 5-fluorouracil drip infusion versus orally UFT in plasma of same patients. Gan To Kagaku Ryoho. 20:1993;1409-1411.
9. Ho D.H., Pazdur R., Covington W., et al. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res. 4:1998;2085-2088.
10. Hoff P.M., Janjan N., Saad E.D., et al. Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer. J Clin Oncol. 18:2000;3529-3534.
11. Kalser M.H., Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 120:1985;899-903.
12. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 230:(776-82):1999;782-784.
13. Liu G., Franssen E., Fitch M.I., Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 15:1997;110-115.
14. Macdonald J.S., Smalley S.R., Benedetti J., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 345:2001;725-730.
15. Minsky B.D., Cohen A.M., Kemeny N., et al. Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol. 10:1992;79-84.
16. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer. 48:1981;1705-1710.
17. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 358:2001;1576-1585.
18. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted- infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 331:1994;502-507.
19. Okabe H., Toko T., Saito H., et al. Augmentation of the chemotherapeutic effectiveness of UFT, a combination of tegafur [1-(2-tetrahydrofuryl)-5- fluorouracil] with uracil, by oral l-leucovorin. Anticancer Res. 17:1997;157-164.
20. Wagman R., Yorke E., Ford E., et al. Respiratory gating for liver tumors: use in dose escalation. Int J Radiat Oncol Biol Phys. 55:2003;659-668.